Results confirm efficacy of B-MS' Opdivo in renal cell carcinoma and in combo with Yervoy in advanced melanoma

6 June 2016

US pharma major Bristol-Myers Squibb (NYSE:BMY) has presented new data on Opdivo (nivolumab) in fighting renal cell carcinoma and on its use with Yervoy (ipilimumab) in advanced melanoma at the 2016 American Society of Clinical Oncology (ASCO) Meeting.

In terms of its research into renal cell carcinoma, the company has presented new long-term overall survival (OS) results from two dose-ranging studies.

These results were from the Phase I CA209-003 study and the Phase II CA209-010 trial, evaluating Opdivo in patients with previously-treated advanced renal cell carcinoma (RCC). Findings include the first report of four and five-year survival data from the advanced RCC cohort study -003, in which OS was an exploratory endpoint.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK